BCTXZ
BriaCell Therapeutics Corp. Warrant
NASDAQ · Healthcare · Biotechnology · CA
$0.19
−2.37%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -30.5%
- EBIT
- -31.1%
- EPS
- +72.2%
- Free cash flow
- -28.8%
- Operating cash flow
- -28.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +17.4%
- Net income
- —
- EPS
- -44.1%
- Free cash flow
- -16.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026